Vitura Health (ASX:VIT) 5-Year Yield-on-Cost %: 7.14 (As of Jul. 14, 2026) — 30% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Vitura Health 5-Year Yield-on-Cost %?

Vitura Health ASX:VIT +10.71% 5-Year Yield-on-Cost % is 7.14 as of Jul. 14, 2026, which is 30% below its 10-year median of 10.20. The stock has 8 warning signs investors should review. Among 516 Drug Manufacturers companies, Vitura Health ranks better than 83.72% on this metric.

Vitura Health's yield on cost for the quarter that ended in Dec. 2025 was 7.14.


The historical rank and industry rank for Vitura Health's 5-Year Yield-on-Cost % or its related term are showing as below:

ASX:VIT' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.75   Med: 10.2   Max: 16.13
Current: 7.14


During the past 7 years, Vitura Health's highest Yield on Cost was 16.13. The lowest was 1.75. And the median was 10.20.


ASX:VIT's 5-Year Yield-on-Cost % is ranked better than
83.72% of 516 companies
in the Drug Manufacturers industry
Industry Median: 2.205 vs ASX:VIT: 7.14

Vitura Health  (ASX:VIT) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Vitura Health 5-Year Yield-on-Cost % Related Terms


ASX:VIT vs ZTS, UTHR: 5-Year Yield-on-Cost % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Vitura Health's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vitura Health 5-Year Yield-on-Cost % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vitura Health's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Vitura Health's 5-Year Yield-on-Cost % falls into.



Vitura Health 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Vitura Health is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 7.14 mean?
Vitura Health (ASX:VIT) has a 5-Year Yield-on-Cost % of 7.14 as of Jul. 14, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Vitura Health and its competitors. This is 30% below median its historical median of 10.20. Over the past decade, Vitura Health's 5-Year Yield-on-Cost % has ranged from 1.75 to 16.13. According to the industry distribution chart, Vitura Health ranks #84 out of 516 companies in the Drug Manufacturers industry, placing it in the top 16.3%.
Is Vitura Health's 5-Year Yield-on-Cost % too high?
Vitura Health's current 5-Year Yield-on-Cost % of 7.14 is 30% below median its 10-year median of 10.20. Over the past 10 years, this metric has ranged from a low of 1.75 to a high of 16.13. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.21. Vitura Health's value of 7.14 is 223.8% above this industry median. Based on the distribution chart, Vitura Health ranks #84 out of 516 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Vitura Health's 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vitura Health ranks #84 out of 516 companies for 5-Year Yield-on-Cost %. This places Vitura Health in the top 16% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 2.21. Vitura Health's value of 7.14 is 223.8% above this benchmark. Historically, Vitura Health's own 5-Year Yield-on-Cost % has ranged from 1.75 to 16.13 over the past decade. While the company's 10-year median is 10.20 vs. the industry median of 2.21, Vitura Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.21, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vitura Health's current 5-Year Yield-on-Cost % of 7.14 is 223.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Vitura Health and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitura Health's current 5-Year Yield-on-Cost % is 7.14, which is 30% below median its own 10-year median of 10.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitura Health stock overvalued right now?
Based on GuruFocus' analysis, Vitura Health (ASX:VIT) is currently considered Significantly Undervalued. The stock's GF Value™ is A$0.10, compared to a current price of A$0.03 — trading 69% below its estimated fair value. The current 5-Year Yield-on-Cost % is 7.14, which is 30% below median its 10-year median of 10.20 and 223.8% above the Drug Manufacturers industry median of 2.21. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Vitura Health (ASX:VIT), the current 5-Year Yield-on-Cost % is 7.14 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vitura Health Business Description

Address 299 Toorak Road, Suite 8, Level 3, South Yarra, VIC, AUS, 3141
Vitura Health Ltd is focused on creating medicinal cannabis products and digital health solutions that connect and strengthen the ecosystem between patients, prescribers, pharmacists, and suppliers. The company has two business segments namely, Sales and distribution (involving the sale and distribution of medical products including medicinal cannabis, psychedelic drugs, and smoking cessation products) and Clinics and services (involving the operation of medicinal cannabis clinics and the provision of related services). The company generates the majority of its revenue from the Sales and distribution segment. Geographically the company generates the majority of its revenue from Australia.